<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424866</url>
  </required_header>
  <id_info>
    <org_study_id>CVBT-2006-PAD-01</org_study_id>
    <nct_id>NCT00424866</nct_id>
  </id_info>
  <brief_title>FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease</brief_title>
  <official_title>A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioVascular BioTherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioVascular BioTherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FGF-1 for the treatment of patients with peripheral arterial disease with intermittent&#xD;
      claudication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FGF-1 administered by intramuscular injection for the treatment of peripheral arterial&#xD;
      disease with intermittent claudication. Eligible patients are allocated to one of three&#xD;
      treatment arms. Patients within each dosing group will be randomized between study drug and&#xD;
      vehicle control. Safety, pharmacokinetics, and cardiovascular improvement will be evaluated&#xD;
      at day 1 and weeks 1, 4 and 12 post dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability of i.m. injected Cardio Vascu Grow TM, a recombinant Human Fibroblast Growth Factor-1 (FGF-1-141)</measure>
    <time_frame>From enrollment through study completion, an average of 12 weeks</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in safety laboratory measurements at 12 weeks</measure>
    <time_frame>From enrollment through study completion, an average of 12 weeks</time_frame>
    <description>Safety laboratory evaluations on hematology, serum chemistry, and urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma FGF-1 (1-141) pharmacokinetic measurements at pre-dose, 5, 15, and 30 minutes and at 1, 2, 4, 6, 10, and 24 hours</measure>
    <time_frame>From enrollment through study completion, an average of 12 weeks</time_frame>
    <description>Pharmacokinetic plasma concentrations of FGF-1 (1-141)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Stenosis</condition>
  <condition>Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The dosing groups correspond to total doses of 0 µg/kg of FGF-1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human FGF-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FGF-1</intervention_name>
    <description>Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg&#xD;
Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg</description>
    <arm_group_label>Human FGF-1</arm_group_label>
    <other_name>Acidic FGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle: 0 µg/kg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Subjects considered eligible to enter the study must sign an informed consent form&#xD;
             prior to the initiation of any study procedures. In the event that the subject must be&#xD;
             withdrawn and is re-screened for study participation at a later date, a new informed&#xD;
             consent form must be signed. Subjects must be competent to give written informed&#xD;
             consent.&#xD;
&#xD;
          2. Age must be ≥50 and ≤75 years of age with a life expectancy of &gt; 1 year and leg&#xD;
             survival &gt; 6 months. Patients &gt;75 and ≤80 years of age will be considered if they show&#xD;
             no signs of cognitive or muscle function decline and are fully able to comply with the&#xD;
             protocol.&#xD;
&#xD;
          3. Patients must have experienced intermittent claudication for at least 6 months and&#xD;
             have been stable for the past 3 months.&#xD;
&#xD;
          4. Patients must have peripheral arterial disease, as confirmed by a resting ABI ≥0.40&#xD;
             and &lt;0.90 based on at least one leg as measured using both the dorsal pedis and&#xD;
             posterior tibial arteries.&#xD;
&#xD;
          5. Stenosis of &gt;70% up to total occlusion must be present in the popliteal artery and/or&#xD;
             in the tibial peroneal trunk or at least 2 tibial arteries above the ankle without&#xD;
             inflow limitation of the popliteal artery. Adequate popliteal inflow is defined as&#xD;
             continuous flow from the abdominal aorta, iliac, common femoral and superficial&#xD;
             femoral with any stenosis &lt; 50% as determined either by intra-arterial DSA, CTA or Gd&#xD;
             CE-MRA.&#xD;
&#xD;
          6. The screening Gardner treadmill test peak walking times (PWT) must be &gt;1 minute and &lt;&#xD;
             12 minutes and limited by pain in one or both calves.&#xD;
&#xD;
          7. Preexisting medication regime must be stable for 6 weeks preceding dosing.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Evidence of critical leg ischemia, i.e. ischemic rest pain or ischemic ulceration&#xD;
&#xD;
          2. Treadmill walking limited by conditions other than intermittent claudication including&#xD;
             arthritis, angina and dyspnea&#xD;
&#xD;
          3. Lower limb amputation of, or in, either leg including toes&#xD;
&#xD;
          4. Evidence of limb ischemia from immunologic or inflammatory disorders&#xD;
&#xD;
          5. Leg surgery or revascularization within past 6 months or peripheral angioplasty within&#xD;
             past 3 months or anticipated during study&#xD;
&#xD;
          6. Participation in any investigational device or drug trial within the past 6 months&#xD;
&#xD;
          7. Myocardial infarction, unstable angina, stroke or ischemic attack within past 6 months&#xD;
&#xD;
          8. New York Heart Association (NYHA) class II, III or IV heart failure, restrictive or&#xD;
             hypertrophic cardiomyopathy or severe valvular disease&#xD;
&#xD;
          9. QTc elongation greater than 450 ms in males or 460 ms in females&#xD;
&#xD;
         10. PT (INR), PTT, urinalysis, thyroid function (T3, T4, TSH) outside normal limits&#xD;
&#xD;
         11. Hemorrhage or thrombotic events (e.g. deep vein thrombosis) within past 6 months&#xD;
&#xD;
         12. Thrombocytopenia (&lt;100,000/µl), history of heparin-induced thrombocytopenia&#xD;
&#xD;
         13. Major surgery with the past 6 months&#xD;
&#xD;
         14. Positive proliferative retinopathy exam&#xD;
&#xD;
         15. Present of any type of cancer or history of cancer except past (but not present) basal&#xD;
             cell dermal carcinoma not on either leg&#xD;
&#xD;
         16. Inflammatory or progressive fibrotic or myelofibrotic disorders&#xD;
&#xD;
         17. Patients experiencing bacterial or viral infection (e.g. hepatitis or HIV) or who may&#xD;
             otherwise be febrile&#xD;
&#xD;
         18. Hemoglobin A1c(HgbA1c) of &gt;8%&#xD;
&#xD;
         19. Type I diabetes&#xD;
&#xD;
         20. Total fasting cholesterol &gt;200&#xD;
&#xD;
         21. Uncontrolled hypertension (≥160 systolic or ≥100 diastolic pressure) or hypotension&#xD;
             (&lt;90 systolic or &lt;60 diastolic pressure)&#xD;
&#xD;
         22. Disease or drug (e.g. systemic corticosteroid) immuno-compromised&#xD;
&#xD;
         23. Hepatic dysfunction as defined either by AST or ALT &gt; 2.0 times the upper limit of&#xD;
             normal&#xD;
&#xD;
         24. Serum creatinine of ≥ 2.5 mg/dl&#xD;
&#xD;
         25. Proteinuria (urine protein/creatinine ratio &gt; 3)&#xD;
&#xD;
         26. Antiproliferative drugs (e.g. thalidomide, hydroxyurea)&#xD;
&#xD;
         27. Radiation therapy&#xD;
&#xD;
         28. Implanted devices not compatible with strong magnetic fields&#xD;
&#xD;
         29. Life expectance of less than 1 year&#xD;
&#xD;
         30. Females who are premenopausal and not sterilized or using adequate birth control or&#xD;
             are either pregnant, intend to become pregnant or are nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Warren Sherman, MD</last_name>
    <phone>(972) 681-9368</phone>
    <email>wsherman@cvbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Nedella</last_name>
    <phone>(972) 681-9368</phone>
    <email>anedella@cvbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CVBT Info</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Intermittent Claudication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

